BRD2 and breast carcinoma: This is the first study in which side effects are shown to be clustered and it is also the first study about side effects of breast cancer treatment in clearly defined pre- and postmenopausal women, in which menopausal status was defined not only by the last menstrual period but also by serum levels of FSH and oestradiol.